A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Lymfactin (AdAptVEGF-C Adenoviral Vector) in Combination With a Surgical Lymph Node Transfer for the Treatment of Patients With Secondary Lymphedema

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 26 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AdVEGF-Herantis (Primary)
Indications Lymphoedema
Focus Adverse reactions; First in man
Sponsors Herantis Pharma

Most Recent Events

20 Apr 2023 Status changed from active, no longer recruiting to discontinued.
27 Aug 2019 Planned End Date changed from 1 Mar 2024 to 1 Feb 2024.
16 Apr 2018 According to a Herantis Pharma media release, company has announced positive interim data from all 15 patients recruited. This study continues with a 12-month follow-up on the patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight